Neumora Therapeutics (NMRA) Interest & Investment Income (2022 - 2025)
Neumora Therapeutics' (NMRA) quarterly Interest & Investment Income came in at -$9000.0 in Q4 2025, down 100.22% year-on-year from $4.1 million in Q4 2024, and down 100.53% quarter-over-quarter from $1.7 million in Q3 2025.
Neumora Therapeutics (NMRA) Interest & Investment Income (2022 - 2025) Analysis & Trends
Neumora Therapeutics' Interest & Investment Income history runs 4 years deep, the most recent figure standing at -$9000.0 for Q4 2025.
- On a quarterly basis, Interest & Investment Income fell 100.22% year-over-year to -$9000.0 in Q4 2025; TTM through Mar 2026 was $1.7 million, a 79.69% decrease from a year earlier, with the FY2025 full-year figure at -$62000.0, down 100.31% from the prior year.
- Interest & Investment Income declined to -$9000.0 in Q4 2025 per NMRA's latest filing, from $1.7 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $4.2 million in Q3 2024 and bottomed at -$284000.0 in Q3 2022.
- The 4-year median for Interest & Investment Income is $64000.0 (2023), against an average of $756142.9.
- Biggest YoY gain for Interest & Investment Income was 2972.26% in 2024; the steepest drop was 113.66% in 2024.
- Year by year, Interest & Investment Income stood at $380000.0 in 2022, then sank by 38.16% to $235000.0 in 2023, then surged by 1639.57% to $4.1 million in 2024, then sank by 100.22% to -$9000.0 in 2025.
- Per Business Quant, the three latest NMRA Interest & Investment Income figures stand at -$9000.0 (Q4 2025), $1.7 million (Q3 2025), and -$12000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Neumora Therapeutics | 299.49 Mn | 299.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -9,000.00 |
| Sep 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | -12,000.00 |
| Mar 31, 2025 | -65,000.00 |
| Dec 31, 2024 | 4.09 Mn |
| Sep 30, 2024 | 4.21 Mn |
| Jun 30, 2024 | -39,000.00 |
| Mar 31, 2024 | -65,000.00 |
| Dec 31, 2023 | 235,000.00 |
| Sep 30, 2023 | 137,000.00 |
| Jun 30, 2023 | -150,000.00 |
| Mar 31, 2023 | 476,000.00 |
| Dec 31, 2022 | 380,000.00 |
| Sep 30, 2022 | -284,000.00 |